Expensive blood safety initiatives may offer less benefit than we think

Mads Kamper-Jørgensen; Henrik Hjalgrim; Gustaf Edgren; Kjell Titlestad; Henrik Ullum; Agneta Shanwell; Marie Reilly; Mads Melbye; Olof Nyrén; Klaus Rostgaard

doi:10.1111/j.1537-2995.2009.02374.x

Expensive blood safety initiatives may offer less benefit than we think

Mads Kamper-Jørgensen, Henrik Hjalgrim, Gustaf Edgren, Kjell Titlestad, Henrik Ullum, Agneta Shanwell, Marie Reilly, Mads Melbye, Olof Nyrén, Klaus Rostgaard

Afdeling for Klinisk Immunologi

8 Citationer (Scopus)

Abstract

Various blood safety initiatives have ensured a historically low risk of infection transmission through blood transfusion. Although further prevention of infection transmission is possible through, for example, nucleic acid testing and future introduction of pathogen inactivation, such initiatives are very costly in relation to the benefit they offer. Although estimation of the cost-effectiveness requires detailed information about the survival of transfusion recipients, previous cost-effectiveness analyses have relied on incorrect survival assumptions.

Originalsprog	Engelsk
Tidsskrift	Transfusion
Vol/bind	50
Udgave nummer	1
Sider (fra-til)	240-2
Antal sider	3
ISSN	0041-1132
DOI	https://doi.org/10.1111/j.1537-2995.2009.02374.x
Status	Udgivet - 1 jan. 2010

Adgang til dokumentet

10.1111/j.1537-2995.2009.02374.x

Citationsformater

@article{56ae3753d5f447c4a1fce0bc22889f17,

title = "Expensive blood safety initiatives may offer less benefit than we think",

abstract = "Various blood safety initiatives have ensured a historically low risk of infection transmission through blood transfusion. Although further prevention of infection transmission is possible through, for example, nucleic acid testing and future introduction of pathogen inactivation, such initiatives are very costly in relation to the benefit they offer. Although estimation of the cost-effectiveness requires detailed information about the survival of transfusion recipients, previous cost-effectiveness analyses have relied on incorrect survival assumptions.",

author = "Mads Kamper-J{\o}rgensen and Henrik Hjalgrim and Gustaf Edgren and Kjell Titlestad and Henrik Ullum and Agneta Shanwell and Marie Reilly and Mads Melbye and Olof Nyr{\'e}n and Klaus Rostgaard",

year = "2010",

month = jan,

day = "1",

doi = "10.1111/j.1537-2995.2009.02374.x",

language = "English",

volume = "50",

pages = "240--2",

journal = "Transfusion",

issn = "0041-1132",

publisher = "Wiley-Blackwell Publishing, Inc",

number = "1",

}

TY - JOUR

T1 - Expensive blood safety initiatives may offer less benefit than we think

AU - Kamper-Jørgensen, Mads

AU - Hjalgrim, Henrik

AU - Edgren, Gustaf

AU - Titlestad, Kjell

AU - Ullum, Henrik

AU - Shanwell, Agneta

AU - Reilly, Marie

AU - Melbye, Mads

AU - Nyrén, Olof

AU - Rostgaard, Klaus

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Various blood safety initiatives have ensured a historically low risk of infection transmission through blood transfusion. Although further prevention of infection transmission is possible through, for example, nucleic acid testing and future introduction of pathogen inactivation, such initiatives are very costly in relation to the benefit they offer. Although estimation of the cost-effectiveness requires detailed information about the survival of transfusion recipients, previous cost-effectiveness analyses have relied on incorrect survival assumptions.

AB - Various blood safety initiatives have ensured a historically low risk of infection transmission through blood transfusion. Although further prevention of infection transmission is possible through, for example, nucleic acid testing and future introduction of pathogen inactivation, such initiatives are very costly in relation to the benefit they offer. Although estimation of the cost-effectiveness requires detailed information about the survival of transfusion recipients, previous cost-effectiveness analyses have relied on incorrect survival assumptions.

U2 - 10.1111/j.1537-2995.2009.02374.x

DO - 10.1111/j.1537-2995.2009.02374.x

M3 - Journal article

C2 - 19761551

SN - 0041-1132

VL - 50

SP - 240

EP - 242

JO - Transfusion

JF - Transfusion

IS - 1

ER -

Expensive blood safety initiatives may offer less benefit than we think

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater